NASDAQ:HTBX - Heat Biologics Stock Price, News & Analysis

Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX."

Heat Biologics shares reverse split on the morning of Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split.

Heat Biologics Inc (NASDAQ:HTBX) posted its quarterly earnings data on Thursday, November, 15th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.21) by $0.05. The biopharmaceutical company earned $1.84 million during the quarter, compared to the consensus estimate of $1.50 million. Heat Biologics had a negative return on equity of 68.17% and a negative net margin of 319.80%. View Heat Biologics' Earnings History.

Heat Biologics is scheduled to release their next quarterly earnings announcement on Tuesday, August 20th 2019. View Earnings Estimates for Heat Biologics.

3 brokerages have issued 1 year target prices for Heat Biologics' shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate Heat Biologics' stock price to reach $6.6667 in the next twelve months. This suggests a possible upside of 1,069.6% from the stock's current price. View Analyst Price Targets for Heat Biologics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heat Biologics.

Headlines about HTBX stock have been trending negative this week, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Heat Biologics earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Heat Biologics.

Heat Biologics saw a drop in short interest during the month of July. As of July 31st, there was short interest totalling 366,600 shares, a drop of 40.9% from the June 30th total of 620,500 shares. Based on an average daily trading volume, of 363,400 shares, the days-to-cover ratio is presently 1.0 days. Currently, 1.2% of the company's shares are short sold. View Heat Biologics' Current Options Chain.

Some companies that are related to Heat Biologics include China SXT Pharmaceuticals (SXTC), Aridis Pharmaceuticals (ARDS), Neurotrope (NTRP), Ovid Therapeutics (OVID), Aravive (ARAV), Catabasis Pharmaceuticals (CATB), Infinity Pharmaceuticals (INFI), vTv Therapeutics (VTVT), Otonomy (OTIC), Spring Bank Pharmaceuticals (SBPH), Inflarx (IFRX), Adamis Pharmaceuticals (ADMP), Novan (NOVN), VBI Vaccines (VBIV) and Marinus Pharmaceuticals (MRNS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Frontier Communications (FTR), Palatin Technologies (PTN), Alibaba Group (BABA), Opko Health (OPK), Juno Therapeutics (JUNO), Synergy Pharmaceuticals (SGYP), TherapeuticsMD (TXMD), Sophiris Bio (SPHS), AVEO Pharmaceuticals (AVEO) and CytRx (CYTR).

Heat Biologics' stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.90%). View Institutional Ownership Trends for Heat Biologics.

HTBX stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for Heat Biologics.

Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of HTBX stock can currently be purchased for approximately $0.57.

Heat Biologics has a market capitalization of $19.42 million and generates $5.79 million in revenue each year. The biopharmaceutical company earns $-15,730,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Heat Biologics employs 30 workers across the globe.View Additional Information About Heat Biologics.

The official website for Heat Biologics is http://www.heatbio.com/.

Heat Biologics' mailing address is 801 CAPITOLA DRIVE, DURHAM NC, 27713. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected]